Delivery Order HHSN261201200015I-HHSN26100006
Award Date 9/18/14
Potential Completion Date 12/17/16
Potential Value $568K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19111, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a cost-no-fee delivery order awarded by the National Cancer Institute (NCI) to The Institute for Cancer Research, a non-profit subsidiary of Temple University. The $598,689 contract is for the modulation of cigarette smoke-induced alterations of microRNA expression and lung tumors in mice treated with aspirin and naproxen. This work is being performed under the NCI's Preclinical Efficacy and Intermediate Endpoint Biomarkers multiple-award indefinite delivery contract, which encompasses...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Purchase Order to Mirimus, Inc., a self-certified small disadvantaged business, for $17,147.50. The contract is for the provision of custom vector expressions. Mirimus, Inc. specializes in engineering mouse models with reversible gene silencing capabilities using RNA interference and has provided scientific supplies, reagents, custom vector...
- This is a $249,167.58 firm fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Gempharmatech LLC, a foreign-owned for-profit biotech company. The contract is for the development of humanized mouse models for nicotinamide N-methyltransferase (NNMT) and sulfotransferase (SULT1A1) using CRISPR knock-in technology. The contractor will conduct biochemical testing of inhibitors and...
- This contract award to Gempharmatech LLC, a foreign-owned biotechnology company in San Diego, California, is for a $58,936 fixed-price purchase order to evaluate the safety of the compound YC1 in mice with humanized SULT1A1 proteins versus standard mouse SULT1A1 proteins. The contract was awarded by the National Center for Advancing Translational Sciences (NCATS), which operates under the National Institutes of Health within the Department of Health and Human Services. The objective is to...
- This federal contract award, with ID HHSN276201000481P, was issued by the National Institute of Diabetes and Digestive and Kidney Diseases, a civilian agency, to Affymetrix, Inc., a for-profit manufacturer, for the purchase of TAS::75 0884::TAS GENECHIP MIRNA ARRAY products. The contract has a ceiling value of $5,400.00 and was awarded on June 16, 2010, with a completion date of June 22, 2010. The contract was a purchase order with an "Other" pricing type, and it did not have a...
- This federal contract was awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration. The $614,898.50 definitive contract is for the analysis of 2,000 urine samples to test for tobacco-related biomarkers including cotinine, trans-3'-hydroxycotinine,...
- This is a delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit research organization, to develop a standard guideline protocol for rodent tobacco smoke inhalation studies. The contract has a ceiling value of $1,373,599.00 and is a firm fixed-price task order issued under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The...
- This is a $1,847,030 delivery order contract awarded by the Food and Drug Administration (FDA) to Battelle Memorial Institute, a nonprofit research and development organization. The contract is for comparative pharmacokinetics and in vivo genetic toxicology studies of N-Nitrosonornicotine (NNN) in rats. The work is being performed under the FDA's "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract has a firm fixed price...
- This firm-fixed-price delivery order was issued under the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The $1,412,105.00 contract was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute, a non-profit contract research organization. The contract is for the...
- This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Mirimus, Inc., a self-certified small disadvantaged business. The $17,147.50 contract is for the delivery of custom vector expressions to support biomedical research. Mirimus is a provider of customized mouse models and reagents, specializing in reversible gene silencing technologies. In addition to...
- HHSN261201200015IIndefinite Delivery Contract
- HHSN261201200015I-HHSN26100006Delivery Order
HHSN2610006 TITLE: MODULATION OF MIRNA EXPRESSION IN BLOOD OR OTHER BIOLOGICAL FLUIDS COMPARED WITH TISSUE LEVELS IN MICE EXPOSED TO CIGARETTE SMOKE AND/OR WITH NSAIDS. PERIOD OF PERFORMANCE: 09/18/2014-09/17/2016
Posted 9/18/14
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Preclinical Efficacy and Intermediate Endpoint Biomarkers | N01CN25002-78 | Department of Health and Human Services National Institutes of Health | Award Notice 2/3 | 2/27/12, 1:10 PM | |
Preclinical Efficacy and Intermediate Endpoint Biomarkers | N01CN25002-78 | Department of Health and Human Services National Institutes of Health | Award Notice 3/3 | 3/13/12, 3:37 PM | |
Preclinical Efficacy and Intermediate Endpoint Biomarkers | N01CN25002-78 | Department of Health and Human Services National Institutes of Health | Award Notice 1/3 | 12/15/11, 3:10 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| 5 | Close Out | ($8k) | 4/13/17 | |
| 4 | Other Administrative Action | $0 | 4/10/17 | |
| 3 | Other Administrative Action | $0 | 4/1/15 | |
| 2 | Other Administrative Action | $0 | 3/12/15 | |
| 1 | Other Administrative Action | $0 | 12/22/14 |